90 citations
,
August 2006 in “British Journal of Dermatology” This paper describes the PRIDE syndrome associated with epidermal growth factor receptor inhibitors but reports no new clinical results.
57 citations
,
August 2006 in “Journal of the American Academy of Dermatology” This case report describes a woman who developed extensive nonscarring inflammatory hair loss after two years of gefitinib treatment, highlighting potential cutaneous side effects associated with epidermal growth factor receptor blockers.
78 citations
,
June 2005 in “Annals of oncology” This case study reported that a 74-year-old woman with metastatic rectal cancer experienced temporary trichomegaly, or eyelash lengthening, associated with cetuximab treatment, which resolved after discontinuation of the drug.
169 citations
,
September 2002 in “British journal of dermatology/British journal of dermatology, Supplement” This study reports that ZD1839 (Iressa), an anticancer drug, was associated with acneiform eruptions and hair growth abnormalities due to its inhibition of epidermal growth factor receptor signaling in the skin.
107 citations
,
June 1997 in “PubMed” In this study, disrupting the epidermal growth factor receptor in mice led to abnormal hair and skin development, characterized by disorganized hair follicles and systemic disease, providing a model for understanding EGFR's role in skin biology.
252 citations
,
November 1995 in “The EMBO Journal” Blocking EGFR in mice causes hair loss and skin changes.
94 citations
,
February 1994 in “The journal of investigative dermatology/Journal of investigative dermatology” This study concluded that epidermal growth factor may induce a 'catagen-like' phase in human hair follicles by disrupting normal cellular proliferation and migration patterns.
323 citations
,
November 1984 in “Journal of Investigative Dermatology” 112 citations
,
August 1984 in “Journal of Investigative Dermatology”